Skip to main content
Signal8

Q/C TECHNOLOGIES, INC. (QCLS) Form SCHEDULE 13D/A — Nov 20, 2026

$QCLSForm SCHEDULE 13D/AFiled Nov 20, 2026, 8:31 PM ET0001683168-26-009020Original filing

PharmaCyte Biotech filed an amended Schedule 13D disclosing a 49.99% beneficial ownership stake in Q/C Technologies (QCLS) — 8,446,093 common shares — after exchanging 851,304 Series G Long-Term Warrants for 4,982,272 common shares on November 18, 2026. The exchange was priced off QCLS's $0.3101 closing price, with no cash paid by PharmaCyte. As Required Holder of both the Series G and Series H Preferred Stock, PharmaCyte also entered an Omnibus Amendment Agreement with the issuer on November 20, 2026, amending the preferred stock certificates of designations to impose a 49.99% beneficial ownership limitation on conversions and warrant exercises.

Key figures

Shares Owned
8446093
Exchange Shares
4982272
Percent Of Class
49.99%
Exchange Warrants
851304
Dividend Acquired Feb
127296
Dividend Acquired Oct
42432
Exchange Reference Price
$0.3101 per share (closing price on last trading day before Consent Agreement)
Beneficial Ownership Limit
49.99% of outstanding Common Stock
Dividend Acquisition Price
$3.3717 per share
Series HMaturity Extended To
September 2, 2027
Series HMaturity Extended From
March 2, 2027

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.